Posters

Dynamic changes of ICL vault after myopic phakic lens implantation

Poster Details

First Author: Š.Skorkovská CZECH REPUBLIC

Co Author(s):    K. Skorkovska   A. Cunderlova   J. Vaverka              

Abstract Details

Purpose:

To evaluate the early changes in the central vault after EVO Visian® ICL implantation to correct moderate to high myopia and to assess the correlation between vault changes and other relevant factors affecting vault.

Setting:

NeoVize Eye Clinic Brno, Czech Republic

Methods:

The prospective study included 35 eyes of 29 females and 6 males, mean age 28.54 (22-36), mean spherical equivalent –9.47 ± 3.71 diopters (D) (range: –5.5 to –12.25 D) who underwent EVO Visian® ICL implantation (26 eyes with myopic Evo Visian®ICL, 9 eyes with myopic toric EVO Visian®ICL). Besides a complete ophthalmologic examination, the central vaulting was measured with OCT to evaluate the changes in follow-up (1 week, 1 and 3 months) and other factors affecting vault was investigated - anterior chamber depth (ACD) and horizontal white to white diameter (WTW).

Results:

The mean postoperative vault after 1 week was 495.89 ± 120.07 µm while the mean ICL vault after 1 month was 521.32 ± 155.72 µm, and the central vault at 3 months after surgery was 517.89 ± 160.07 µm. There was significant difference between the vault at 1 week and 1 and 3 month after surgery (P = 0.02, P =0.03), while no significant difference was between the vault at 1 and 3 month after surgery (P = 0.08). The central vault was positively correlated with ACD (r = 0.366, P = 0.022), and WTW (r =0.344, P = 0.034)

Conclusions:

Our results demonstrated the dynamic changes in vault of phakic ICL in eyes in the 1 week, 1 and 3months period following ICL implantation. We concluded that preoperative ACD and WTW are contributing factors affecting the vault postoperatively. There was a trend for the phakic IOL vaults to increase from 1 week to 1 month after surgery with the vault tending to stabilize from 1 to 3 months postoperatively.

Financial Disclosure:

None